Drug Trial Radar · NCT04109950
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
463
Actual
Start
Nov 20, 2019
Primary completion
Nov 9, 2023
Study completion Nov 9, 2023
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with schizophrenia. Participants in the study will receive the drug being studied. This study is accepting male and female participants between 13 and 65 years old who have been diagnosed with schizophrenia and have completed Study SEP361-301 (NCT04072354) or Study SEP361-302 (NCT04092686). This study will be conducted in approximately 80 study centers worldwide. The treatment duration for this study is one (1) year.
Conditions
- Schizophrenia
Interventions
SEP-363856Drug
SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of overall Adverse Events (AEs), Serious Adverse Events (AEs), and Adverse Events (AEs) leading to discontinuationTime frame: 53 Weeks
Locations
78 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Little Rock, Arkansas
Research Site
Rogers, Arkansas
Research Site
Anaheim, California
Research Site
Culver City, California
Research Site
Lemon Grove, California
Research Site
Long Beach, California
Research Site
Long Beach, California
Research Site
Montclair, California
Research Site
San Diego, California
Research Site
Sherman Oaks, California
Research Site
Miami Springs, Florida
Research Site
Oakland Park, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Lake Charles, Louisiana
Research Site
Gaithersburg, Maryland
Research Site
Flowood, Mississippi
Research Site
St Louis, Missouri
Research Site
Marlton, New Jersey
Research Site
New York, New York
Research Site
Dayton, Ohio
Research Site
Austin, Texas
Research Site
Richardson, Texas
Research Site
Burgas, Bulgaria
Research Site
Kardzhali, Bulgaria
Research Site
Novi Iskar, Bulgaria
Research Site
Pazardzhik, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vratsa, Bulgaria
Research Site
Barranquilla, Colombia
Research Site
Bogotá, Colombia
Research Site
Zagreb, Croatia
Research Site
Daugavpils, Latvia
Research Site
Riga, Latvia
Research Site
Strenči, Latvia
Research Site
Chelyabinsk, Russia
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.